Home > For Consumers > Is adding focused radiation...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2003-. doi: 10.1002/14651858.CD006121.pub3

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet].

Is adding focused radiation (radiosurgery) to whole brain radiation therapy beneficial to patients with brain metastases?

This version published: 2016; Review content assessed as up-to-date: August 07, 2012.

Link to full article: [Cochrane Library]

Plain language summary

We identified three RCTs that looked at whether adding focused radiation (radiosurgery) to whole brain radiation therapy (WBRT) is beneficial to patients with brain metastases. Most of our conclusions are based on the results of one large trial with unclear prejudice and therefore, we cautiously make the following remarks: we found that when radiosurgery is added to WBRT, there was no evidence to suggest that patients lived any longer than if they had WBRT alone, except for patients with only one brain metastasis (who may live longer if they receive the combination treatment). Patients in the combination treatment also seemed to function better in daily life, their treated tumors were associated with having less chance of growing back, and they had to take less steroid medication. The side effects of combined therapy and WBRT alone were similar.

Abstract

Background: Historically, whole brain radiation therapy (WBRT) has been the main treatment for brain metastases. Stereotactic radiosurgery (SRS) delivers high‐dose focused radiation and is being increasingly utilized to treat brain metastases. The benefit of adding SRS to WBRT is unclear. This is an updated version of the original Cochrane review published in Issue 6, 2010.

Objectives: To assess the efficacy of WBRT plus SRS versus WBRT alone in the treatment of brain metastases.

Search methods: In the original review we searched the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 2, 2009), MEDLINE (1966 to 2009), EMBASE (1980 to 2009), and CancerLit (1975 to 2009) in order to identify trials for inclusion in this review.

In this update we searched the following electronic databases in May 2012: Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 5, 2012), MEDLINE (2009 to May week 4 2012), and EMBASE (2009 to 2012 week 21) in order to identify trials for inclusion in the review.

Selection criteria: The review was restricted to randomized controlled trials (RCTs) that compared use of WBRT plus SRS versus WBRT alone for upfront treatment of adult patients with newly diagnosed metastases (single or multiple) in the brain resulting from any primary, extracranial cancer.

Data collection and analysis: The Generic Inverse Variance method, random‐effects model in RevMan 5 was used for the meta‐analysis.

Main results: A meta‐analysis of two trials with a total of 358 participants, found no statistically significant difference in overall survival (OS) between WBRT plus SRS and WBRT alone groups (hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.65 to 1.02). For patients with one brain metastasis median survival was significantly longer in WBRT plus SRS group (6.5 months) versus WBRT group (4.9 months; P = 0.04). Patients in the WBRT plus SRS group had decreased local failure compared to patients who received WBRT alone (HR 0.27; 95% CI 0.14 to 0.52). Furthermore, a statistically significant improvement in performance status scores and decrease in steroid use was seen in the WBRT plus SRS group. Unchanged or improved Karnofsky Performance Scale (KPS) at 6 months was seen in 43% of patients in the combined therapy group versus only 28% in WBRT group (P = 0.03). Overall, risk of bias in the included studies was unclear.

Authors' conclusions: Since the last version of this review no new studies were found that met the inclusion criteria. Given the unclear risk of bias in the included studies, the results of this analysis have to be interpreted with caution. Analysis of all included patients, SRS plus WBRT, did not show a survival benefit over WBRT alone. However, performance status and local control were significantly better in the SRS plus WBRT group. Furthermore, significantly longer OS was reported in the combined treatment group for recursive partitioning analysis (RPA) Class I patients as well as patients with single metastasis.

Editorial Group: Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group.

Publication status: Edited (no change to conclusions).

Citation: Patil CG, Pricola K, Sarmiento JM, Garg SK, Bryant A, Black KL. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD006121. DOI: 10.1002/14651858.CD006121.pub3. Link to Cochrane Library. [PubMed: 22972090]

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PMID: 22972090

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...